Diabetes Drug Delivery Methods - Market and Technologies - Biologics Market Research

Diabetes Drug Delivery Methods - Market and Technologies
Frost & Sullivan
June 9, 2006
193 Pages
Pub ID: MC1305725
US $6,500.00 Electronic Access - Single User
US $8,000.00 Electronic Delivery - Global Site License
US $7,000.00 Hard Copy Mail Delivery

Abstract
Countries covered: Global
Research Overview
This Frost & Sullivan research service titled Drug Delivery for Diabetes-Market and Technologies provides an overview of advancements in drug delivery technologies in diabetes. It also provides a description of the revenues generated by present insulin delivery methods along with a complete analysis of key market drivers, restraints and trends prevailing in the European market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: insulin syringes, insulin pens, insulin pumps and inhaled insulin.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
Insulin Syringes
Insulin Pens
Insulin Pumps
Inhaled Insulin
Technologies
The following technologies are covered in this research:
Inhaled insulin
Oral insulin
Transdermal insulin
Nanotechnology
Diabetes vaccine
Gene therapy
Market Overview
Non-invasive Insulin Delivery to Significantly Improve Diabetes Management
The growing demand for non-invasive delivery of insulin, particularly inhaled insulin, is leading to increased focus on the diabetes drug delivery market in Europe. Moreover, due to the irregularity exhibited by a significant number of patients in following insulin therapy, companies are pursuing insulin delivery methods that involve reduced pain, thereby facilitating compliance with the therapy. While various non-invasive delivery methods such as oral insulin, transdermal delivery and nanotechnology are still under research, the overall drug discovery market is anticipated to exhibit strong growth.
"For diabetic patients using insulin injections, who are faced with issues such as infections, improper administration of insulin and uncontrolled blood glucose, alternate insulin delivery methods are likely to offer tremendous benefits," remarks the analyst of this research service. In addition, with the ability of inhaled insulin to offer glycaemic control comparable to insulin injections, such advantages are likely to promote market growth.
Competitive Pricing Key to Market Growth
Despite the potential of the market, long-term safety and efficacy of pulmonary delivery of insulin are factors expected to pose a challenge to market growth. While the Food and Drug Administration (FDA) as well as the European Medical Evaluation Agency (EMEA) have approved Exubera (the first inhaled insulin to enter the market), occurrences of pulmonary fibrosis during clinical trials are causing concerns about its safety. Hence, pharmaceutical companies involved in the research of inhaled insulin devices will need to focus on long-term safety of emerging insulin delivery methods.
At the same time, novel insulin delivery methods, such as transdermal insulin delivery, are anticipated to gain prominence across Europe "The reimbursement of inhaled insulin, which relies on its cost effectiveness as well as patient compliance, is likely to be hampered by its high prices," says the analyst. "Hence, the advantages of convenience, safety and accuracy of inhaled insulin in comparison to conventional insulin, will need to be proved to justify the high costs."